CD79A and COVID-19: Taken all COVID-19 patients in the acute phase, we detected a positive correlation between IL-6 and anti-Spike IgA levels (r=0.3517, p=0.0004) (Supplementary Figure 7A), and anti-RBD IgA levels (r=0.3247, p=0.0010) (Supplementary Figure 7B), although there was no correlation between IL-6 and anti-Spike IgG, anti-RBD IgG and anti-NP IgG, IgA, IgM levels (Supplementary Figures 7A–C).